Cargando…
BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
Despite the advent of new therapies and improved outcomes in patients with pulmonary arterial hypertension (PAH), it remains a life-shortening disease and the time to diagnosis remains unchanged. Strategies to improve outcomes are therefore currently focused on earlier diagnosis and a treatment appr...
Autores principales: | Lewis, Robert A., Durrington, Charlotte, Condliffe, Robin, Kiely, David G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488846/ https://www.ncbi.nlm.nih.gov/pubmed/32414745 http://dx.doi.org/10.1183/16000617.0009-2020 |
Ejemplares similares
-
Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023) -
Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables
por: Curiati, Milena Novaes Cardoso, et al.
Publicado: (2013) -
Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors
por: Alawieh, Hussein, et al.
Publicado: (2019) -
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
por: Palazzuoli, A, et al.
Publicado: (2010) -
The Ability of Heart Failure Specialists to Accurately Predict NT-proBNP Levels Based on Clinical Assessment and a Previous NT-proBNP Measurement
por: Sedlak, Tara L, et al.
Publicado: (2008)